Peptilogics
Michael Jones is an experienced finance professional with a robust background in accounting and financial reporting. Currently, Michael serves as Corporate Controller at Peptilogics, a position held since January 2022. Prior to this, Michael was the Controller at Cognition Therapeutics, Inc. from March 2020 to December 2021, and the Director of Accounting and Finance - Assistant Controller at BlueRock Therapeutics from September 2018 to March 2020. Michael's extensive experience also includes significant roles at PTC Therapeutics, Inc., where responsibilities spanned from Director, Accounting & Financial Reporting to Manager, External Financial Reporting, along with six years at Ernst & Young as Manager, Assurance Services. Educational qualifications include a Master of Accountancy in Financial Accounting from Rutgers Business School and a Bachelor of Science in Management with a concentration in Accounting from Boston College, graduating Magna Cum Laude.
This person is not in any offices
Peptilogics
Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space, but ensuring that each potential therapeutic is biologically viable and scalable to manufacture. Peptilogics' lead clinical stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need.